Positive CHMP Opinion for Tevimbra (tislelizumab) as a first-line treatment for nasopharyngeal cancer – Beigene
BeiGene, Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion recommending approval of Tevimbra (tislelizumab), in combination with gemcitabine… read more.
